Autism Reality

Autism & Mercury – Wagnitz Challenges Fombonne

The mercury autism debate continues. While not a subscriber to the mercury vaccine/autism link I do not think debate and discussion should be closed on this or any other subject related to autism. Toxicologist Michael Wagnitz seems somewhat more qualified to present information on the “mercury” side of the debate than David Kirby and presents some interesting points in rebuttal of Psychiatrist Dr. Eric Fombonne.


The mercury, autism debacle: How stupid do they think we are?

Michael Wagnitz
May 7, 2007

Last weekend the Sixth International Meeting for Autism Research took place in Seattle. The meeting claimed to draw the top 900 autism researchers and scientists from around the world. One of the key participants was Dr. Eric Fombonne of Montreal Children’s Hospital at McGill University. Dr. Fombonne, a psychiatrist, presented his research on mercury. His work involved testing the blood and hair of 147 children. Roughly half of his subjects were diagnosed with autism and half were considered neurologically typical controls. He found no difference in mercury levels in the patients hair or blood.

The first question one might ask is why a psychiatrist is considered qualified to do toxicological work. Most parents are concerned about the mercury exposure that their children received as newborns and infants from mandatory vaccines. The vaccine schedule in Canada, where Dr. Fombonnes study was done, and the United States were quite different in the 1990’s. Dr. Fombonne,s patients were not tested after vaccination. If he had talked to any reputable toxicologist, they would have told him that the ethylmercury from vaccines clears the blood in about seven days. Ethylmercury, a short-chain alkyl mercury compound, is rapidly distributed to the brain, kidneys and other tissue. The hair tested would need to be from a first haircut to show this mercury exposure. Even if this was the case, research has shown that autistic kids do not excrete mercury efficiently. The hair would not contain any measurable amounts of mercury. It’s to bad that McGill University does not have any toxicologists who could have explained to Dr. Fombonne that his work was a waste of time and money.

If one was really interested in determining the body burden of mercury they would perform the urinary porphyrin profile analysis (UPPA). Porphyrins are precursors to heme, the oxygen carrying component of blood. Mercury inhibits the conversion of specific porphyrins to heme. This test is backed by decades of published research. Recently it was shown in two published, peer-reviewed studies, that mercury inhibited porphyrins were significantly higher in autistic patients when compared to age matched controls (1)(2). The other way to test for mercury in the body is by using a provoking agent and measuring mercury in the urine.

The organizers of this meeting did not reveal that when Dr. Fombonne isn’t conducting epidemiological studies or doing heavy metal analysis, he is appearing on behalf of vaccine manufacturers defending the safety of mercury. Dr. Fombonne refers to the amount of mercury in vaccines as “trace”. Again, if he were a toxicologist or chemist, he would realize that the concentration of mercury in a multi-dose vaccine vial is 250 times higher than what the United States Environmental Protection Agency (EPA) classifies as hazardous waste.

References:

(1) Nataf R, Lam A, Lathe R, Skorupka, C. 2006. Porphyrinurea in Childhood Autistic Disorders: Implications for Environmental Toxicity. Toxicol. Appl. Pramacol. 214(2):99-108

(2) Geier M, Geier D, 2006. A prospective assessment of porphyrins in autistic disorders: a potential marker for heavy metal exposure. Neurotox Res. Aug;10(1):57-64

About the Author: Michael Wagnitz has over 20 years experience evaluating materials for toxic metals. He currently works as a chemist in the toxicology section of a public health lab evaluating biological samples for lead and mercury.

Michael Wagnitz

http://www.americanchronicle.com/articles/viewArticle.asp?articleID=26477

Advertisements

May 8, 2007 Posted by | autism awareness, autism disorder, David Kirby, Eric Fombonne, Geier, mercury, Michael Wagnitz, thimerosal, vaccines | 1 Comment

Autism & Thimerosal – Geier & Geier (2007) Study Suggests A Link?

One of the great debates in autism discussions has been between those who believe that mercury based vaccine preservatives cause or contribute to incidents of autism and those who do not subscribe to that theory. The overwhelming consensus from the scientific community has been that there is no evidence to support such a link. Notwithstanding that consensus there are still a large number of parents of autistic children ( I am not one of them ) and one journalist/author (David Kirby) who believe that there is indeed a link. A few of the parents have been very vocal. Some, if internet discussions can be believed, have gone as far as harassing and threatening those who oppose their views. At least those are the allegations advanced by some “neurodiversity” commentators some of whom are equally as hostile and rude to those who disagree with their views as the extremist few among the mercury-thimerosal advocacy groups. Now, another study by Geier & Geier (2007) apparently suggests that there is a causal connection between Thimerosal and autism. Hopefully, this study will be neither rejected nor accepted based solely on prior belief. Hopefully the scientific professionals capable of properly analyzing this study will do so and offer their commentary. Hopefully hostility and hatred between the few extremists in both the mercury-vaccine and the neurodiversity groups will stand aside in favor of reason and proper scientific assessment of this study and any further evidence relevant to this issue which might arise.

The following commentary, however, appears to indicate that the old pattern of jumping to conclusions about issues in the mercury-autism debate, based on ideological pre-disposition will, unfortunately, continue to prevail and that the world autism community will be inflicted with more needless hostility between the mercury and neurodiversity groups. The author’s readiness to conclude that the study “leaves little doubt” does not suggest the kind of reasoned professional analysis that will be needed to properly interpret and assess the study.


The Journal of Toxicology and Environmental Health, Part A: Current Issues, an authoritative journal featuring original toxicological research, has published, “A Case Series of Children with Apparent Mercury Toxic Encephalopathies Manifesting with Clinical Symptoms of Regressive Autistic Disorders,” by Geier and Geier (2007).

This new study leaves little doubt there is a direct causal link between mercury exposure from Thimerosal-preserved biological products (vaccines and Rho(D) products) and mercury poisoning diagnosed as an autism spectrum disorder (ASD).

Thimerosal (49.55% mercury by weight) is a highly toxic mercury compound used as a preservative in some OTC and prescription drugs, including most flu shots given to pregnant women, infants, children, adults, and the elderly.

On April 19, 2007, Dr. Larry L. Needham, Chief, Organic Analytical Toxicology Branch, CDC, announced to the US National Academy of Sciences’ Institute of Medicine that Thimerosal was among the “Chemicals Linked to ASD.”

Thus, Geier and Geier (2007) provide the first clinical case-series of ASD patients that confirmed this causal role for Thimerosal-preserved drugs in patients having a regressive ASD diagnosis.

The Geiers describe a case-series of eight patients who had:

— a regressive ASD diagnosis,

— elevated levels of androgens,

— excreted significant amounts of mercury after a chelation challenge,

— biochemical evidence of decreased function in their glutathione pathways,

— no known significant mercury exposures except from Thimerosal-preserved vaccines and Rho(D)-immune globulin preparations, and

— alternative causes for their regressive ASDs ruled out.

This clinical study also found a significant dose-response relationship between the severity of the ASD symptoms and the total mercury dose these children received from Thimerosal-preserved drugs.

Based on differential diagnosis, these patients were exposed to significant mercury amounts from Thimerosal-preserved biologic drugs during their fetal and neonatal development as well as between 12 and 24 months of age. Thus, these initially normally developing children suffered mercury toxic encephalopathies that manifested with clinical symptoms consistent with their regressive ASD diagnosis.

Hence, mercury poisoning should be considered as a cause for those children exhibiting the symptoms of an ASD in any differential diagnosis designed to assess underlying causes.

Today, any parent or other healthcare provider can easily confirm whether, or not, a non-chelated autistic child is mercury poisoned by having urinary porphyrin profile analysis (UPPA) testing run at LabCorp (Test#120980) or Laboratoire Philippe Auguste (Urine Porphyrin Profile).

For additional information on UPPA testing for mercury poisoning, please visit the “UPPA” page on CoMeD’s web site, http://www.Mercury-freeDrugs.org.

Dr. King
http://www.dr-king.com

http://www.medicalnewstoday.com/medicalnews.php?newsid=69427

May 1, 2007 Posted by | autism disorder, CDC, David Kirby, Dr. King, Dr. Larry Needham, Geier, mercury, neurodiversity, thimerosal, vaccines | 5 Comments

The Autism Knowledge Revolution

We are living in a revolutionary era. The hardware era is giving away to the software age, and as a result, the economic and social landscape of the world is undergoing seismic changes. The Knowledge Revolution, Noel M. Tichy, Ph.D., 2002

The world is awakening now to another knowledge based revolution – the revolutionary explosion in our knowledge of autism disorders. Like other revolutions the Autism Knowledge Revolution also promises to be seismic in its impact. Recent autism reports have brought news of the Autism Genome Project with studies providing new information about the genetic bases of autism disorders. Gene mutations are being identified as the cause of some instances of autism. A new study suggests that the amygdala, a part of the brain associated with emotional learning and fear, shrinks in people with autism, as a result of chronic stress caused by social fear in childhood.

Like other revolutions there are those who fear the onset of the Autism Knowledge Revolution and its impact. They stand on principle and cloak their fears in the mantle of human rights. Fear mongering is already spreading in relation to genetic research in autism with wild speculation about what the purveyors of such fear describe as a eugenics program similar to some of history’s worst atrocities. Others express a more practical fear; that our rapidly increasing knowledge in the genetics of autism will be of no value to older autistic children and adults. As the father of a severely autistic 11 year old boy I understand that particular fear but I do not believe that genetic research will yield only clues to prevention of autism occurrence or education of the very young. It is quite possible that our knowledge of autism disorders will assist in understanding how autism works in all individuals with an autism disorder and that may lead to new ways of understanding autistic persons and how to enhance their lives.

Hopefully one result of the Autism Knowledge Revolution will be the end of some of the needless hostility surrounding the vaccine/mercury autism debate. The believers in the Mercury Theory have clung to their theory with almost no scientific support and have resorted in desperation to belief in a world wide conspiracy involving “big pharma”, big government and a “bought and paid for” world science community doing the bidding of Big Pharma. Some opponents of the Mercury Theory have been just as virulent and would censor any reference to autism as a disorder, disease or medical condition by any term. More research, more knowledge, may well show some environmental factors in the onset of autism, mercury based or otherwise. Or it may disprove conclusively any such connections.

The future holds promise but never provides promises or guarantees. Some of the research currently under way may lead to dead ends; part of the scientific process of elimination. But the increase in knowledge of autism will undoubtedly increase our uderstanding of autism. Surely a good thing in and of itself.

The autism knowledge revolution does provide hope, hope of a cure for those who seek it for themselves or their loved ones. It is a hope based not on resignation or “acceptance of autism”. It is a hope based on solid scientific research as most of our advances of the last 300 years have been. There are no limits at this time on where this knowledge might lead. While concern that it will not assist older autistic persons is understandable it does not automatically follow that such research will be of no benefit to them and all autistic persons, regardless of age.

Those of us who are not ourselves scientists, and do not imagine ourselves to be scientists, can still assist by involvement in organizations, such as Autism Speaks, and CAIRN (Canadian Association Intervention Research Network), which have been such powerful positive forces in the advancement of autism research.

We can all lobby, create public awareness and raise funds.

We can all join the Autism Knowledge Revolution.

March 18, 2007 Posted by | autism, Autism Genome Project, Autism Knowledge Revolution, autism research, autism speaks, CAIRN, mercury | Leave a comment

Immunologist Responds to Wagnitz Mercury-Autism Link Argument

The Capital Times (Madison, Wisconsin) carried an opinion piece recently by Michael Wagnitz, a chemist with years of experience in trace analysis, who argued that the brains of some deceased autistic persons showed evidence of neuroinflammation which he attributed to mercury poisoning from the vaccine preservative thimerosal. On that basis Mr. Wagnitz argued that thimerosal poisoning is a cause of autism. The Capital Times has now published a passionate response to the Wagnitz argument by Cheryl A. Robinson, R.N., M.S., immunization program manager, public health, Madison and Dane county.

http://www.madison.com/tct/opinion/letters/index.php?ntid=121460&ntpid=2

Ms. Robinson takes particular aim at Wagnitz’s dismissal of epidemiological evidence refuting a thimerosal-autism link:

The real disservice to your readers was Michael Wagnitz’s dismissal of a vast body of epidemiological evidence. These studies compared large groups of children who received thimerosal-containing vaccine to large numbers of children who did not get these vaccines. The occurrence of autism in each group was the same. While no one believes that mercury is healthy for children or adults, there is simply no evidence demonstrating that thimerosal in vaccine causes or is linked to autism.

Developmental problems are most often noticed when children reach the age of 1 or 2 years – a time when children also receive a large number of immunizations. I understand how easy it is for families to link the two events.“

Ms. Robinson also notes that vaccines in the US are now thimerosal free, with the exception of influenza vaccine for which a thimerosal free version can be requested. She accuses Wagnitz of the kind of alarmism which drives some parents to avoid immunization an unwise decision which poses a genuine threat to public health.

Personally I have not been a subscriber to the mercury-autism link theory and do not think parents should avoid immunizing their children but I thought Mr. Wagnitz argument about neuro-inflammation interesting. Further scientific study and evidence may yet reveal some connection. We certainly should not stop looking at the best available evidence even if it contradicts our own views. I find discussions such as are taking place in the opinion pages of the Madison Capital Times helpful in understanding these issues and the developing state of scientific knowledge surrounding them.

March 4, 2007 Posted by | autism disorder, Capital Times, Madison, mercury, neuroinflammation, Robinson, thimerosal, vaccines, Wagnitz | Leave a comment

Too Soon to Write Off a Possible Mercury (Thimerosal) Autism Link ?

I have personally never been a believer in possible alleged mercury (thimerosal) autism link. Primarily because I accept the overwhelming consensus in the world scientific community that there is no link. Second, because I don’t believe in the conspiracy angle of those who postulate a mercury autism link. Third, for personal reasons, my son displayed unusual behavior, which we have documented in a large photograph collection, since birth. None the less I think that Michael Wagnitz has made a very interesting argument for the mercury vaccine connection. Mr. Wagnitz is a chemist with 20 years experience working trace metal analysis who argues that recent findings of clinical studies examining brain tissue, blood, urine and human cells make a strong case for thimerosal as the agent causing the neuroinflammation which has been found in the brains of deceased autistic persons. The following article in the Madison Wisconsin Capital Times is worth a read. It will be interesting to read critiques of Mr. Wagnitz’ theory but for now at least maybe it is worth waiting for more study before writing off the mercury-autism link.

Michael Wagnitz: Research supports mercury-autism link

By Michael Wagnitz

It was reported repeatedly in 2006 that the link between mercury-containing vaccines and autism has been disproven. Yet if one looks at the most recent research coming from some of our major universities, one may draw the opposite conclusion.

What we have learned in the last couple of years is that the underlying medical condition of autism is neuroinflammatory disease. In a study conducted at John Hopkins University, brain tissue from deceased autistic patients was examined. The tissue showed an active neuroinflammatory process and marked activation of microglia cells. Neuroinflammatory disease is synonymous with an activation of microglia cells.

A study done at the University of Washington showed that baby primates exposed to injected thimerosal (50 percent mercury), at a rate equal to the 1990s childhood vaccine schedule, retained twice as much inorganic mercury in their brains as primates exposed to equal amounts of ingested methylmercury. We know from autometallographic determination that inorganic mercury present in the brain, following the dealkylation of organic mercury, is the toxic agent responsible for changes in the microglial population and leads to neuroinflammation.

Recently it was shown that in more than 250 examined patients, atypical urinary porphyrins were almost three times higher in autistic patients than controls. Porphyrins are precursors to heme, the oxygen-carrying component of blood. Mercury inhibits the conversion of porphyrins to heme. When the patients were treated to remove mercury, urinary porphyrins returned to normal levels.

In a study done at the University of Arkansas, autistic children were found to have significantly lower levels of the antioxidant glutathione. Glutathione is the major antioxidant needed for the elimination of mercury at the cellular level. This may explain why some children are more severely affected by thimerosal in vaccines than others.

While all the government-conducted epidemiological (statistical) studies show no link between thimerosal and autism, the clinical studies examining brain tissue, blood, urine and human cells show a completely different picture.

Michael Wagnitz is a Madison resident with more than 20 years of experience as a chemist working with trace metal analysis.

Published: February 27, 2007

http://www.madison.com/tct/opinion/column/index.php?ntid=120748&ntpid=1

February 27, 2007 Posted by | autism disorder, John Hopkins University, mercury, neuroinflammation, thimerosal, Wagnitz | 1 Comment

Combating Autism Act Spurs Autism Research

The following article from the Psychiatric Times gives a good, digestible, overview of some of the autism studies currently being conducted even as the Combating Autism Act spurs more research.


New Act by Congress Gives Boost to Autism Research
By Arline Kaplan

February 2007, Vol. XXIV, No. 2

The passage and signing in December of the Combating Autism Act (S. 843), which authorizes $945 million over 5 years for research, screening, intervention, and education on autism spectrum disorders (ASD) and developmental disabilities, has been hailed by the advocacy group Cure Autism Now (CAN) as a “federal declaration of war on the epidemic of autism,” a disorder that affects 1 in 166 children. 1 Yet, some battles are already under way at NIMH’s Intramural Research Program, with patient recruitment proceeding for 3 major autism studies.

In a press statement, Jonathan Shestack, father of an autistic child and cofounder of CAN, a large private funding organization for autism research, said S. 843 (now Public Law 109-416) “creates a congressionally mandated road map for a federal assault on autism, including requirements for strategic planning, budget transparency, congressional oversight, and a substantial role for parents of children with autism in the federal decision-making process.”

Key provisions of the law, subject to the availability of appropriations, call for the following:

* Expanded research on ASD, including basic and clinical research in such fields as pathology, developmental neurobiology, genetics, pharmacology, nutrition, immunology, neurobehavioral development, and toxicology.
* The CDC to increase and update its efforts to monitor autism incidence and prevalence around the country and to support the establishment of regional Centers of Excellence in the epidemiology of ASDs and other developmental disabilities.
* Development of a curriculum for continuing education to assist in recognizing the need for valid and reliable screening tools and in using those tools.
* Early screening of individuals at higher risk for ASD and other developmental disabilities.
* Congressional oversight of the Autism Centers of Excellence.
* Expansion and reauthorization of the Interagency Autism Coordinating Committee, composed of relevant government officials, experts, families of those with ASD, and at least one individual who has ASD.

Autism trials

The NIMH studies on the NIH campus in Bethesda, Md, are the first products of a new, integrated focus on autism. One study, “Clinical and Immunological Investigations of Sub-types of Autism,” seeks to learn more about autism and its subtypes. “It is actually two studies in one,” said Susan Swedo, MD, chief of NIMH’s Pediatrics and Developmental Neuropsychiatry Branch.

The first is a study of regressive versus nonregressive autism to determine whether there is an immune or other systemic trigger of children’s neurologic regression, she said. It involves 50 children with idiopathic autism and regression, 50 children with idiopathic autism and no history of regression, 25 children with Rett syndrome, and 50 healthy children. The age range of all 4 groups is between 12 months and 48 months at first visit.

The second component to the study, Swedo said, is part of the Autism Phenome Project, a pilot investigation being conducted in collaboration with David Amaral, PhD, Beneto Foundation Professor and director of research at the M.I.N.D. Institute at the University of California, Davis. Between the 2 sites, the pilot phase of the phenome study involves 50 to 100 children with autism, 50 children with developmental delays, and 50 to 100 children without disorders. The purpose is to identify clinically meaningful subtypes of autism, which could lead to better understanding of the etiology and pathophysiology of the disorder.

Increasingly, researchers are considering that autism may be multiple disorders. The regressive subtype is well characterized, Swedo said, although there is some debate about how common it is. The reports vary from indicating that as few as 10% to as many as 40% of children with autism have a pattern of regression.

With regressive autism, Swedo explained, you have a history of the child developing typically until age 12 to 18 months with appropriate development of language and social skills and then the child loses words and social skills and begins to look indistinguishable from children who have had autistic symptoms from birth or early on.“Some investigators have found that the regressive subtype actually has a worse prognosis,” she said.

To explain the regression, Swedo said that the research team’s working hypothesis is that there are environmental triggers or perhaps genetic aberrations that are expressed at this particular point in the child’s development. One possibility based on Swedo’s work with obsessive-compulsive disorder and the pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections subgroup is that regressive autism develops following a viral or bacterial infection that triggers an autoimmune response and neuropsychiatric symptoms.

The phenome study includes questions related to a child’s exposure to environmental toxins and household products; neuroimaging (structural MRI); and biomarkers; as well as very careful behavioral, neurologic (eg, via electroencephalograms administered while the child sleeps in the hospital overnight), and physical assessments. “The children will be monitored every 6 months to a year until they are age 5, and then intermittently after that time” to examine the validity of their diagnosis and how their symptom course evolves over time, Swedo added.

Minocycline study

In another small-scale intramural study, Treatment of Childhood Regressive Autism With Minocycline: An Anti-Inflammatory Agent Active Within the CNS, NIMH researchers are examining the use of the antibiotic minocycline (Dynacin, Minocin, Myrac) in children aged 3 to 12 years with regressive autism.

“We are using minocycline, a tetracycline derivative, not for its effectiveness as an antibiotic but rather for its ability to modulate the immune system,” Swedo said. “It has fairly specific effects on NF-kappa B and therefore inhibits the initiation of the cascade that leads to inflammation. Published data from the Johns Hopkins group [2,3] demonstrate that brains of individuals with autism have evidence of chronic neuroinflammation. We hope that by stopping that process, the children will be able to recover some of their skills. We are conducting an open-label trial in 10 children and are accepting referrals. If the results are encouraging, we will do a placebo-controlled trial in a larger cohort of subjects.”

Asked about other pharmacologic approaches being investigated at NIMH, Swedo responded, “We have a few in [the] pipeline, but it is premature to talk about them. Eric Hollander, MD, has been doing some work with oxytocin, reported at the American College of Neuropsychopharmacology’s annual meeting.”

Hollander, chairman of psychiatry at the Mt Sinai School of Medicine in New York and director of the Seaver and New York Autism Center of Exellence, and Jennifer Bartz, PhD, found that pitocin (synthetic oxytocin), administered intravenously or nasally, may have significant positive effects in adults with autism. Oxytocin, a hormone that is best known for activity during birth and lactation, is also a brain neurotransmitter involved in social recognition and bonding.

Chelation therapy

The third NIMH study, “Mercury Chelation to Treat Autism,” seeks to address whether chelation therapy can be helpful for autism. The chelation study is a placebo-controlled trial that involves use of meso-2,3-dimercaptosuccinic acid (DMSA, succimer), an orally adminstered chelating agent that binds to all metals including mercury and lead but also to some beneficial metals, such as zinc and iron, according to Swedo. DMSA is commonly used to treat autism, with some surveys estimating that 1 in 12 children with autism has undergone chelation, although it has never been tested in a controlled study and there is no proof that it helps children with the disorder. Support for its use is based on single-case reports of benefits of chelation with DMSA.

Children aged 4 to 10 years in whom autism, Asperger disorder, or pervasive child developmental disorders have been diagnosed; who weigh at least 33 lb; who have detectable, but not toxic, levels of mercury or lead in the blood; and who have not previously received chelation therapy may be eligible for this study.

“The chelation study is based on the hypothesis that mercury toxicity is responsible for at least some cases of autism,” Swedo said. She explained that extensive controversy surrounds the issue of mercury toxicity in autism. The Institute of Medicine (IOM) conducted a comprehensive study of the question of whether thimerosal, an ethylmercury-based compound used previously in the United States as a vaccine preservative for routine childhood immunizations, contributed to the apparent increase in the prevalence of ASDs. 4 The IOM panel concluded that there was no evidence for an association, but the report has been dismissed by some parents who report “toxic mercury levels” among their affected children and who have observed benefits of open-label DMSA administration.

To answer the question in a controlled fashion, the NIMH will enroll about 120 children in the chelation study, with half randomized to placebo and half to DMSA. The trial will last for 6 months, and researchers are enrolling participants now. “We would love to receive referrals,” Swedo said, adding that psychiatrists can find out more by going to http://www.clinicaltrials.gov or by contacting Lorraine Lougee, LCSW, research coordinator. Lougee’s e-mail address is LougeeL@intra.nimh.nih.gov.

Incidence and prevalence

Because of recurrent questions about whether autism is increasing, Swedo was asked about incidence and prevalence. “We have absolutely no data on incidence,” she said. “We can say the disorder appears to be more prevalent now than it has been reported in the past. However, there was a major change in diagnostic criteria and case-finding methods, so it is unclear [whether] it represents a true change in rates of affected individuals. . . . The CDC is conducting several studies currently to address that question.”

There is increasing agreement on what true autism is, using the Autism Diagnostic Observational Schedule, a semistructured observational scale developed to assess social interaction, communication, and play in persons suspected of having autism, and the Autism Diagnostic Interview, Swedo said.

“Those 2 give you nice, reliable cutoffs where you can say a child has autism, is on the autism spectrum, or is developing typically. Including children on the autism spectrum will increase apparent prevalence rates,” Swedo said. “The figure of 1 in 166 children having autism was recently confirmed in a CDC study that reviewed school records and confirmed the diagnosis from medical records. But the study included all children with an ASD as having ‘autism’—this included not only severely affected individuals with full-blown autism but also those with a pervasive developmental disorder not otherwise specified and those with Asperger disorder, a condition [that] is not as impairing.”

“In order to determine the true prevalence of autism and to know whether there is an ‘epidemic’ as some have asserted,” Swedo continued, “we need to have better data about the current prevalence of autism and related disorders and then compare those data with comparable data from previous studies. The CDC is conducting surveillance studies at a number of US sites, and the NIH is sponsoring longitudinal investigations here and abroad to address those questions.”

References

1. Centers for Disease Control and Prevention. How common are autism spectrum disorders (ASD)? Available at: http://www.cdc.gov/ncbddd/autism/asd_common.htm. Accessed January 5, 2007.
2. Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry. 2005;17:485-495.
3. Vargas DL, Nascimbene C, Krishnan C, et al. Neuroglial activation and neuroinflammation in the brain of patients with autism [published correction appears in Ann Neurol. 2005;57:304]. Ann Neurol. 2005;57:67-81.
4. Board on Health Promotion and Disease Prevention, Institute of Medicine. Immunization Safety Review: Vaccines and Autism (2004). Available at: http://www.nap.edu/books/030909237X/html/1.html. Accessed January 5, 2007.

http://www.psychiatrictimes.com/showArticle.jhtml?articleId=197002523&pgno=1

February 27, 2007 Posted by | Asperger Disorder, autism disorder, chelation, Combating Autism Act, diagnosis, mercury, minocycline, neuroinflammation, oxytocin, PDD-NOS, prevalence, Psychiatric Times, thimerosal | Leave a comment

Mayo Clinic – No Evidence to Support Chelation Autism Treatment – Can Be Dangerous

In this comment Dr. Hoecker of the Mayo Clinic states that there is no evidence to support Chelation as an autism treatment. Chelation can be dangerous – even deadly.

http://www.mayoclinic.com/health/autism-treatment/AN01488


There’s no scientific evidence that chelation therapy is an effective autism treatment.

In recent years, some doctors and parents have recommended chelation therapy as a potential treatment for autism. Proponents believe that autism is caused by mercury exposure, such as from childhood vaccines. Chelation therapy supposedly removes mercury from the body, which cures autism.

But extensive studies have revealed no evidence of a link between mercury exposure and autism. In addition, chelation therapy is not approved as an autism treatment and can be associated with serious side effects, including liver and kidney damage that can result in death.

There is no cure for autism. As a result, unproven alternative therapies are often suggested to parents who — frustrated by the lack of effective medical treatment for autism — are desperate to find something that will help their children. However, in clinical studies, these alternative therapies are usually found to be ineffective and sometimes harmful. Talk to your son’s doctor before starting any alternative autism treatment.

Although no cure for autism exists, early behavioral and educational interventions can help children with autism improve their communication and social skills.

January 27, 2007 Posted by | autism disorder, chelation, health, mercury, treatment, vaccines | Leave a comment